{"id":"W4413394227","doi":"10.1093/ehjcvp/pvaf064","title":"Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF","year":2025,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Montreal Heart Institute; Health Care Foundation","funders":"American Regent; National Institutes of Health; Novo Nordisk; University of Glasgow; ARCA Biopharma; LivaNova; Boston Scientific Corporation; Alexion Pharmaceuticals; Novartis Portugal; Alnylam Pharmaceuticals; Idorsia Pharmaceuticals; British Heart Foundation; Brigham and Women's Hospital; Intas Pharmaceuticals; Eli Lilly and Company; AstraZeneca; Bayer; Amgen; American Heart Association","keywords":"Medicine; Valsartan; Sacubitril, Valsartan; Sacubitril; Internal medicine; Clinical endpoint; Enalapril; Ejection fraction; Logistic regression; Cardiology; Quality of life (healthcare); Heart failure; Clinical trial; Angiotensin-converting enzyme; Blood pressure","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001325601,0.0002992118,0.0007071688,0.000198926,0.0001275853,0.0003855899,0.0001832689,0.0003354482,0.0009626105],"category_scores_gemma":[0.001170972,0.0001447147,0.0009008732,0.0002712306,0.0001977495,0.0002870762,0.0002158549,0.0006669978,0.00008528581],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002953539,"about_ca_system_score_gemma":0.0002733055,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001080506,"about_ca_topic_score_gemma":0.002504124,"domain_scores_codex":[0.9995381,0.0002382681,0.00004330231,0.00006095293,0.00006031789,0.00005916884],"domain_scores_gemma":[0.9991836,0.0002338823,0.0003462964,0.00003486147,0.00004236324,0.0001590147],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2150236,0.00211949,0.7275547,0.0006287102,0.005196022,0.0001600899,0.0001243328,0.00166943,0.002194915,0.0002158781,0.0008591033,0.04425383],"study_design_scores_gemma":[0.01190337,0.02768022,0.9525499,0.00007483119,0.002508744,0.0001983348,0.0001271447,0.003380201,0.0005501194,0.0002308284,0.0007689469,0.00002728807],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967007,0.002628607,0.00005221607,0.00008737536,0.00001735716,0.00001393065,0.0001733312,0.000003500481,0.0003230973],"genre_scores_gemma":[0.9990583,0.0003793095,0.0000780688,0.00006048301,0.0000243502,0.00001439108,0.0002614557,5.956376e-7,0.0001230369],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001325601,"threshold_uncertainty_score":0.007010579,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1390294972912309,"score_gpt":0.3345118815845112,"score_spread":0.1954823842932804,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}